Loading...
OTCM
INBP
Market cap5mUSD
Oct 08, Last price  
0.19USD
1D
0.53%
1Q
15.39%
Jan 2017
-16.13%
Name

Integrated Biopharma Inc

Chart & performance

D1W1MN
OTCM:INBP chart
P/E
—
P/S
0.13
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.67%
Rev. gr., 5y
-7.15%
Revenues
44m
-19.28%
60,160,00049,940,00039,367,00037,019,00025,133,00036,604,00033,623,00033,683,00037,488,00042,214,00046,954,00043,710,00049,977,00052,769,00063,559,00056,246,00050,672,00050,317,00054,353,00043,872,000
Net income
-3m
L
-2,044,000-18,167,000-18,176,000-5,535,000-2,281,000-2,713,00093,000131,000735,000958,0002,346,000679,0001,688,0004,108,0008,013,0003,838,000-34,000112,000808,000-2,842,000
CFO
1m
-39.90%
-5,502,000-4,298,000-2,752,000-116,000390,000-771,000-1,438,0001,877,000-113,000-594,000397,0001,168,000328,0001,339,0003,050,0004,091,0001,232,000943,0002,065,0001,241,000
Dividend
Aug 19, 20080.5 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Key people

E. Gerald Kay
Executive Chairman of the Board · since 2019
Dina L. Masi
Chief Financial Officer, Senior Vice President, Secretary · since 2005
Carl DeSantis
Director · since 2003
Christina Kay
Co-Chief Executive Officer, Executive Vice President, Director · since 2019
William H. Milmoe
Director · since 2008
Riva Sheppard
Co-Chief Executive Officer, Executive Vice President, Director · since 2019
Robert Canarick
Independent Director · since 1994
URL
https://ir.ibiopharma.com
IPO date
Oct 30, 1996
Employees
147
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT